Welcome to Novatek Pharmaceuticals

Novatek Pharmaceuticals  is a company that focuses on the potentially beneficial roles of TQ against COVID-19 pathophysiology in the context of antioxidant, anti-inflammatory, immunomodulatory, epigenetic modulation, antiviral activity, docking studies on anti-COVID-19 activity, antibacterial and anticoagulant effects for the treatment of COVID-19.

What is a black seed? The Black Seed is scientifically known as Nigella Sativa. The plant grows about 40-60cm in height, and from it comes many small rectangular Black Seed, quite commonly known as ‘The Blessed Seed’. As well as being a fantastic culinary herb in its own right, it also has many medicinal uses due to its antiviral, anti-inflammatory, anti-fungal, antioxidant, antibacterial, anti-asthmatic, anticoagulant and anti-histimic properties.

Founders Mohamed, Osama and Karim, created Novatek Pharmaceuticals to develop and commercialize an innovative therapeutic approach to treat COVID-19. In other words, our product was driven by wanting to provide effective results to offer great health benefits with quality that lives up to the highest standards.
LEARN MORE

Novatek Pharmaceuticals Inc., was recently formed based on years of experience with thymoquinone in oncology patients combined with recent publications.

LEARN MORE

Novatek Pharmaceuticals main target is the concentrated form of the black seed oil. Black seed oil is a natural product with therapeutic potential in management of SARS-CoV-2 due to its anti-viral activity.
LEARN MORE

We provide scientific guidance to the Consortium and advice on the strategic direction of our Project scientific guidance
LEARN MORE

Thymoquinone may block the SARS-CoV-2 entry via ACE2 in pneumocytes. N. sativa oil and thymoquinone produce antinociceptive effects through indirect activation of supraspinal μ1- and κ-opioid receptor subtypes.
LEARN MORE

There is a pending story in collaboration with case CWRU School of Medicine to study the effect of TQ formula and cancer patients. Stay current with the latest news and events from Novatek Pharmaceuticals.
COMING SOON

Novatek Pharmaceuticals Initiates a Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, TQ Formula, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting
LEARN MORE

In order to best meet our patients needs, Pyramids Pharmacy delivers Ground or Overnight, five days a week. You can be confident the medications will be delivered when needed.
LEARN MORE

In order to best meet our patients needs, Pyramids Pharmacy delivers Ground or Overnight, five days a week. You can be confident the medications will be delivered when needed.
LEARN MORE

Stay current with the latest news and events from Novatek Pharmaceuticals.
LEARN MORE

Novatek Pharmaceuticals Initiates a Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, TQ Formula, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting
LEARN MORE

Thymoquinone may block the SARS-CoV-2 entry via ACE2 in pneumocytes. N. sativa oil and thymoquinone produce antinociceptive effects through indirect activation of supraspinal μ1- and κ-opioid receptor subtypes.
LEARN MORE

We provide scientific guidance to the Consortium and advice on the strategic direction of our Project scientific guidance
LEARN MORE

Novatek Pharmaceuticals main target is Black seed oil. Black seed oil is a natural product with therapeutic potential in management of SARS-CoV-2 due to its anti-viral activity.
LEARN MORE

Novatek Pharmaceuticals Inc., was recently formed based on years of experience with thymoquinone in oncology patients combined with recent publications.

LEARN MORE

Founders Mohamed, Osama and Karim, created Novatek Pharmaceuticals to develop and commercialize an innovative therapeutic approach to treat COVID-19. In other words, our product was driven by wanting to provide effective results to offer great health benefits with quality that lives up to the highest standards.
LEARN MORE

Novatek Pharmaceuticals Initiates a Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, TQ Formula, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting
LEARN MORE

What we do

Novatek Pharmaceuticals main target is Black seed oil. Black seed oil is a natural product with therapeutic potential in management of SARS-CoV-2 due to its anti-viral activity.
LEARN MORE

Novatek Pharmaceuticals was founded by Dr. Ahmed Kaseb, MD.
Dr. Kaseb is a Professor at the University of Texas, MD Anderson Cancer Center.
LEARN MORE

Who we are

Novatek Pharmaceuticals Inc., was recently formed based on years of experience with thymoquinone in oncology patients combined with recent publications.

LEARN MORE

Connect with us

In order to best meet our patients needs, Pyramids Pharmacy delivers Ground or Overnight, five days a week. You can be confident the medications will be delivered when needed.
LEARN MORE

Stay current with the latest
news and events from Novatek Pharmaceuticals.
LEARN MORE

Thymoquinone may block the SARS-CoV-2 entry via ACE2 in pneumocytes. N. sativa oil and thymoquinone produce antinociceptive effects through indirect activation of supraspinal μ1- and κ-opioid receptor subtypes.
LEARN MORE

We provide scientific guidance to the Consortium and advice on the strategic direction of our Project scientific guidance
LEARN MORE

About Our Products

Black seed oil is a natural product with therapeutic potential in management of SARS-CoV-2 due to its anti-viral activity. Derived from Nigella Sativa plant, it has been extensively studied and shown to possess a wide spectrum of activities which include antibacterial, antifungal and antiviral effects among many others. Most of the therapeutic properties are due to thymoquinone, a major bioactive constituent of N. sativa seeds.

PRESS RELEASE:

Novatek Pharmaceuticals Initiates A Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, TQ Formula, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting

Contact Us

Based on NIH guidelines there are five categories of COVID-19 disease severity. The least severe category designation is “Non-hospitalized, Mid to Moderate COVID-19”. Thymoquinone is the only current orally-administered treatment targeted to this COVID-19 patient category.

For more information, please contact us.

Please contact us